Nerispirdine hydrochloride

N/A

Report date: 2023/04/21 09:51:04
NME

Base Information

Drug NameNerispirdine hydrochloride
Drug Alias Namenerispirdina奈立吡啶奈利吡啶nerispirdinumNerispirdine +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockersPotassium channel blockersAcetylcholine receptor; alpha1/beta1/delta/gamma agonists
TargetsPotassium channelSodium channel alpha subunitAcetylcholine receptor; alpha1/beta1/delta/gamma
Therapy Area/IndicationsNeuritisSpinal Cord InjuriesMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNorway +[10] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi
Active IndicationsN/A
Inactive IndicationsNeuritisSpinal Cord InjuriesMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A